Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone evaluation in HIV-positive women over 40 switching from TDF-based NNRTI regimen to Triumeq
2015-005297-37Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Switch to Triumeq with Continue current Truvada/NNRTI regimen (2 arms). Primary endpoint: Change in total hip bone mineral density at week 48. Started Jan 2016; status: completed.
02
Drugs
abacaviremtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-005297-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005297-37.